• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Long‐term outcomes of pulmonary vein isolation in patients with Brugada Syndrome and paroxysmal atrial fibrillation

byDavy LauandAlex Chan
July 27, 2022
in Cardiology, Chronic Disease
Reading Time: 2 mins read
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Share on FacebookShare on Twitter

1. At 58 months follow-up, fewer patients with Brugada Syndrome (BrS) and associated paroxysmal atrial fibrillation (AF) achieved freedom from atrial tachyarrhythmias, following pulmonary vein isolation (PVI) catheter ablation, compared to non-BrS patients with paroxysmal AF.

2. Rates of freedom from AF were similar between BrS and non-BrS patients with a history of paroxysmal AF.

3. Rates of inappropriate shocks from implantable cardioverter-defibrillators (ICDs) were significantly lower following PVI catheter ablation, compared to prior.

Evidence Rating Level: 2 (Good)

Atrial fibrillation (AF) is the most frequent supraventricular arrhythmia that occurs in patients with Brugada syndrome (BrS), an inherited arrhythmia syndrome. Pharmacological treatment for AF in BrS patients is complex due to a risk of drug-related ventricular arrhythmias. Catheter ablation is an option, which for BrS patients involves pulmonary vein isolation (PVI), although the pathophysiology of the condition is unclear regarding whether pulmonary veins are an appropriate target. Therefore, this cohort study examined the long-term outcomes of PVI in BrS patients with paroxysmal AF compared to AF patients without BrS, including freedom from atrial tachyarrhythmias and prevalence of inappropriate shocks from implantable cardioverter-defibrillators (ICDs). The study population consisted of 60 BrS patients with paroxysmal AF, or AF that ceases within 7 days, either with treatment or spontaneously. Each patient underwent PVI between 2012 and 2019 and was propensity-matched to a participant without BrS or structural heart disease, but with symptomatic paroxysmal AF treated with PVI. Antiarrhythmic medications were discontinued 3 months following ablation. The study showed that after a mean follow-up of 58.2±31.7 months, more non-BrS patients achieved freedom from atrial tachyarrhythmias, with 61.7% of BrS patients compared to 78.3% of non-BrS patients (log-rank p = 0.047). However, rates of freedom from AF were similar, with 76.7% of BrS patients and 83.3% of non-BrS patients (log-rank p = 0.27). Additionally, ICD-inappropriate shocks were less prevalent after ablation, with 27.6% reporting inappropriate shocks prior to ablation, and 3.4% afterwards (p = 0.01). Overall, this study demonstrated that BrS patients with AF did have a lower long-term rate of freedom from atrial tachyarrhythmias following PVI, compared to non-BrS AF patients, but that AF freedom rates were similar.

Click to read the study in JAHA

RELATED REPORTS

Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections

Most routine blood tests do not require prolonged fasting

Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Intravenous tenecteplase non-inferior to alteplase for thrombolysis in acute ischemic stroke

Next Post

Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

RelatedReports

Infectious Disease

Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections

October 9, 2026
2 Minute Medicine

Most routine blood tests do not require prolonged fasting

October 9, 2026
Artificial Intelligence

Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases

October 9, 2026
Chronic Disease

Low-dose radiotherapy may be effective as a short-term therapeutic option in knee osteoarthritis

October 8, 2026
Next Post
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Dinoprostone superior to Foley catheter balloon induction for patients with prior C-section

#VisualAbstract: Treatment with 4% albumin post cardiac surgery does not reduce adverse events compared to Ringer acetate

#VisualAbstract: Treatment with 4% albumin post cardiac surgery does not reduce adverse events compared to Ringer acetate

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.